國立虎尾科技大學 |

Precision Medicine in the Age of "Big Data" : = Leveraging Machine Learning and Genomics for Drug Discoveries.

紀錄類型:	書目-語言資料,手稿 : Monograph/item
正題名/作者:	Precision Medicine in the Age of "Big Data" :/
其他題名:	Leveraging Machine Learning and Genomics for Drug Discoveries.
作者:	Gayvert, Kaitlyn M.
面頁冊數:	1 online resource (85 pages)
附註:	Source: Dissertation Abstracts International, Volume: 79-05(E), Section: B.
Contained By:	Dissertation Abstracts International79-05B(E).
標題:	Genetics. -
電子資源:	click for full text (PQDT)
ISBN:	9780355501681

Precision Medicine in the Age of "Big Data" : = Leveraging Machine Learning and Genomics for Drug Discoveries.
Gayvert, Kaitlyn M.

Precision Medicine in the Age of "Big Data" :Leveraging Machine Learning and Genomics for Drug Discoveries. - 1 online resource (85 pages)

Source: Dissertation Abstracts International, Volume: 79-05(E), Section: B.

Thesis (Ph.D.)

Includes bibliographical references

Targeted therapies designed to specifically target molecules involved in carcinogenesis have achieved remarkable antitumor efficacy. However resistance inevitably develops and many cancer patients are not candidates for these targeted therapies. Furthermore the clinical attrition rate continues to rise, which remains a barrier in the development of novel targeted therapies. Integration of extensive genomics datasets with large drug databases allows us to begin to tackle questions about target discovery and drug toxicity with the ultimate goal of accelerating personalized anticancer drug discovery. The purpose of this dissertation was to address these problems through the development of drug repurposing, toxicity prediction, and drug synergy prediction models.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780355501681Subjects--Topical Terms:

578972
Genetics.
Index Terms--Genre/Form:

554714
Electronic books.

Precision Medicine in the Age of "Big Data" : = Leveraging Machine Learning and Genomics for Drug Discoveries.
LDR:03836ntm a2200373Ki 4500 001 911098
005 20180517121919.5
006 m o u
007 cr mn||||a|a||
008 190606s2017 xx obm 000 0 eng d
020 $a 9780355501681
035 $a (MiAaPQ)AAI10602479
035 $a (MiAaPQ)med.cornell:10310
035 $a AAI10602479
040 $a MiAaPQ $b eng $c MiAaPQ
099 $a TUL $f hyy $c available through World Wide Web
100 1 $a Gayvert, Kaitlyn M. $3 1182731
245 1 0 $a Precision Medicine in the Age of "Big Data" : $b Leveraging Machine Learning and Genomics for Drug Discoveries.
264 0 $c 2017
300 $a 1 online resource (85 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertation Abstracts International, Volume: 79-05(E), Section: B.
500 $a Adviser: Olivier Elemento.
502 $a Thesis (Ph.D.) $c Weill Medical College of Cornell University $d 2017.
504 $a Includes bibliographical references
520 $a Targeted therapies designed to specifically target molecules involved in carcinogenesis have achieved remarkable antitumor efficacy. However resistance inevitably develops and many cancer patients are not candidates for these targeted therapies. Furthermore the clinical attrition rate continues to rise, which remains a barrier in the development of novel targeted therapies. Integration of extensive genomics datasets with large drug databases allows us to begin to tackle questions about target discovery and drug toxicity with the ultimate goal of accelerating personalized anticancer drug discovery. The purpose of this dissertation was to address these problems through the development of drug repurposing, toxicity prediction, and drug synergy prediction models.
520 $a First to target the role of transcription factors as drivers of oncogenic activity, we developed a computational drug repositioning approach (CRAFTT) that makes predictions about drugs that specifically disrupt transcription factor activity. To do this, CRAFTT integrates transcription factor binding site information with drug-induced expression profiling. We found that CRAFTT was able to recover a significant number of known drug-transcription factor interactions and identified a novel interaction that we subsequently validated. Our work in drug discovery led us to ask questions about what makes a drug safe. We developed a data-driven approach (PrOCTOR) that integrates the properties of a compound's targets and its structure to directly predict the likelihood of toxicity in clinical trials and was able to accurately classify known safe and toxic drugs. Finally to address the problem of drug resistance, we developed a machine learning approach to identify synergistic and effective drug combinations based on single drug efficacy information and limited drug combination testing. When applied to mutant BRAF melanoma, this approach exhibited significant predictive power upon evaluation with cross-validation and further experimental testing of previously untested drug combinations in cell lines independent of the training set.
520 $a Altogether this work demonstrates how the integration of orthogonal datasets gives us power to address difficult questions that are critical for precision medicine and drug discovery. Approaches such as these have the potential to make a direct impact on how patients are treated, as well as to help prioritize and guide additional focused studies.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Genetics. $3 578972
650 4 $a Artificial intelligence. $3 559380
655 7 $a Electronic books. $2 local $3 554714
690 $a 0369
690 $a 0800
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Weill Medical College of Cornell University. $b Computational Biology and Medicine. $3 1182732
773 0 $t Dissertation Abstracts International $g 79-05B(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10602479 $z click for full text (PQDT)